Alice Huntsman-Labed

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

Thomas Fischer, Richard M. Stone, Daniel J. DeAngelo et al. · Journal of Clinical Oncology · 2010 · 502 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia

Richard M. Stone, Thomas Fischer, Ron Paquette et al. · Leukemia · 2012 · 273 citations · Full text

Medicine, Hematology, Oncology +13

Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial

Ravi Savarirayan, Louise Tofts, Melita Irving et al. · The Lancet · 2020 · 198 citations

Medicine, Pediatrics, Pharmacotherapy +2

Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study

Ravi Savarirayan, Louise Tofts, Melita Irving et al. · Genetics in Medicine · 2021 · 99 citations · Full text

Medicine, Orthopedic Surgery, Pharmacotherapy +10

Vosoritide therapy in children with achondroplasia aged 3−59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial

Ravi Savarirayan, William R. Wilcox, Paul Harmatz et al. · The Lancet Child & Adolescent Health · 2023 · 64 citations

Pharmacy, Pediatrics, Pharmacotherapy +2